Related references
Note: Only part of the references are listed.Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Ana Cordeiro et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA-CAR-T therapy in patient with relapsed myeloma
Quande Lin et al.
BONE MARROW TRANSPLANTATION (2020)
Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis
Ghady Haider et al.
CLINICAL INFECTIOUS DISEASES (2020)
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha et al.
HAEMATOLOGICA (2020)
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma
Shruti Gupta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Inpatient and Intensive Care Unit Resource Utilization after CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy (CART19) for Pediatric Acute Lymphoblastic Leukemia (ALL)
Regina M. Myers et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Noelle Frey et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Jennifer N. Brudno et al.
NATURE MEDICINE (2020)
Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients
Danielle E. Arnold et al.
PEDIATRIC BLOOD & CANCER (2020)
Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
Shuangyou Liu et al.
BLOOD CANCER JOURNAL (2020)
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
Tania Jain et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Maria-Luisa Schubert et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy
Wenyue Cao et al.
BLOOD (2020)
The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma
Jun-Xia Cao et al.
CYTOTHERAPY (2020)
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
Noelle Frey et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma and chronic lymphocytic leukemia.
Kathryn Cappell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cytokine release syndrome in severe COVID-19
John B. Moore et al.
SCIENCE (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The chimeric antigen receptor -intensive care unit (CAR -ICU) initiative: Surveying intensive care unit practices in the management of CAR T -cell associated toxicities
Cristina Gutierrez et al.
JOURNAL OF CRITICAL CARE (2020)
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
Kitsada Wudhikarn et al.
BLOOD ADVANCES (2020)
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Xian Zhang et al.
BLOOD ADVANCES (2020)
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial
Stephen J. Schuster et al.
BLOOD ADVANCES (2020)
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
Martina Pennisi et al.
BLOOD ADVANCES (2020)
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
Rakesh Awasthi et al.
BLOOD ADVANCES (2020)
American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States
Zahra Mahmoudjafari et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Philipp Karschnia et al.
BLOOD (2019)
Early and late hematologic toxicity following CD19 CAR-T cells
Shalev Fried et al.
BONE MARROW TRANSPLANTATION (2019)
Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators
Mohit Sachdeva et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions
Bradley D. Hunter et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy
Utkarsh H. Acharya et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
Lara L. Riegler et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)
Managing the toxicities of CAR T-cell therapy
Sattva S. Neelapu
HEMATOLOGICAL ONCOLOGY (2019)
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy
Hamza Hashmi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry
Stephan Grupp et al.
BLOOD (2019)
Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
Jia Wei et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
Rebecca A. Gardner et al.
BLOOD (2019)
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
Samantha Jaglowski et al.
BLOOD (2019)
Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)
Marcelo C. Pasquini et al.
BLOOD (2019)
Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib
Tanya Siddiqi et al.
BLOOD (2019)
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas
Jeremy S. Abramson et al.
BLOOD (2019)
Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
Max Topp et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Raza M. Alvi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Management of T-Cell Engaging Immunotherapy Complications
Indumathy Varadarajan et al.
CANCER JOURNAL (2019)
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy
Joshua A. Hill et al.
BLOOD ADVANCES (2019)
In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
Jorge Garcia Borrega et al.
HEMASPHERE (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Hypogammaglobulinemia due to CAR T-cell therapy
Michael A. Pulsipher
PEDIATRIC BLOOD & CANCER (2018)
Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies
Michael D. Jain et al.
STEM CELLS (2018)
The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review
Zhen Jin et al.
ANNALS OF HEMATOLOGY (2018)
Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience
Danielle S. Burstein et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques
Anandani Nellan et al.
BLOOD (2018)
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
Jae H. Park et al.
CLINICAL INFECTIOUS DISEASES (2018)
Albumin infusion improves endothelial function in septic shock patients: a pilot study
Geoffroy Hariri et al.
INTENSIVE CARE MEDICINE (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
David Porter et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products
Kenneth Cornetta et al.
MOLECULAR THERAPY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
David T. Teachey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Interleukin-6: designing specific therapeutics for a complex cytokine
Christoph Garbers et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates
Agne Taraseviciute et al.
CANCER DISCOVERY (2018)
Neurotoxicity after CTL019 in a pediatric and young adult cohort
Jacqueline S. Gofshteyn et al.
ANNALS OF NEUROLOGY (2018)
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema
Matthew Torre et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella et al.
NATURE MEDICINE (2018)
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
Aleksei Titov et al.
CELL DEATH & DISEASE (2018)
Clinical Utilization of Chimeric Antigen Receptors T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation
Ankit J. Kansagra et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Juliane Gust et al.
CNS DRUGS (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
Verena Staedtke et al.
NATURE (2018)
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Karen Thudium Mueller et al.
CLINICAL CANCER RESEARCH (2018)
Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR
Jennifer Brudno et al.
BLOOD (2018)
Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells
Veronika Bachanova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy
Joshua A. Hill et al.
BLOOD (2018)
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
James N. Kochenderfer et al.
MOLECULAR THERAPY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights
Amrom E. Obstfeld et al.
BLOOD (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function
Nathan Singh et al.
CYTOTHERAPY (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review
Scott C. Howard et al.
ANNALS OF HEMATOLOGY (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
Vijay G. Bhoj et al.
BLOOD (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy
Fang Chen et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2016)
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Cameron J. Turtle et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Angelo Ravelli et al.
ARTHRITIS & RHEUMATOLOGY (2016)
765. Treatment of Chemotherapy-Refractory B-Cell Malignancies with Anti-CD19 Chimeric Antigen Receptor T Cells
MOLECULAR THERAPY (2016)
Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide
Alfred L. Garfall et al.
BLOOD (2016)
Long-Lived Plasma Cells Are Contained within the CD19-CD38hiCD138+ Subset in Human Bone Marrow
Jessica L. Halliley et al.
IMMUNITY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
G-CSF and GM-CSF in Neutropenia
Hrishikesh M. Mehta et al.
JOURNAL OF IMMUNOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL
Susan R. Rheingold et al.
BLOOD (2015)
Fluid Resuscitation in Sepsis A Systematic Review and Network Meta-analysis
Bram Rochwerg et al.
ANNALS OF INTERNAL MEDICINE (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
Cornell Assessment of Pediatric Delirium: A Valid, Rapid, Observational Tool for Screening Delirium in the PICU
Chani Traube et al.
CRITICAL CARE MEDICINE (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans
Sabina Guenther et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2014)
Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis
Christopher Uhlig et al.
CRITICAL CARE (2014)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N. Kochenderfer et al.
BLOOD (2013)
Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?
Sjoukje J. C. van der Stegen et al.
JOURNAL OF IMMUNOLOGY (2013)
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
David S. Ritchie et al.
MOLECULAR THERAPY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome
Alexander Astrakhan et al.
BLOOD (2012)
IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
Stefan Rose-John
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
John Scholler et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience
Conrad Russell Cruz et al.
CYTOTHERAPY (2010)
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease
Stefan Stein et al.
NATURE MEDICINE (2010)
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Norihiro Nishimoto et al.
BLOOD (2008)
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo
Kerstin Schwarzwaelder et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Jan-Inge Henter et al.
PEDIATRIC BLOOD & CANCER (2007)
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1
MG Ott et al.
NATURE MEDICINE (2006)
Glucocorticoids in T cell apoptosis and function
MJ Herold et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids
D Czock et al.
CLINICAL PHARMACOKINETICS (2005)
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
S Hacein-Bey-Abina et al.
SCIENCE (2003)
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
S Hacein-Bey-Abina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)